摘要
目的检测血管内皮细胞生长因子(VEGF)在弥漫性大B细胞淋巴瘤(DLBCL)中的临床意义。方法应用ELISA法检测41例DLBCL患者(A组)和36例健康对照者(C组)的血清VEGF水平。记录DLBCL患者临床特征,采用CHOP方案化疗后评价疗效。结果 A组治疗前VEGF水平高于C组[(219.1±34.5)pg/ml vs.(122.6±26.4)pg/ml](P<0.05)。A组化疗有效者VEGF水平治疗后较治疗前明显下降(P<0.05),且在不同乳酸脱氢酶(LDH)水平、临床分期、骨髓浸润及结外病灶数量组中VEGF水平差异有统计学意义(P<0.05)。结论血清VEGF水平与DLBCL的发生发展有关,可用于对化疗疗效和预后的判断。
Objective To investigate the clinical significance of the expression of vascular endothelial growth factor（VEGF） in the diffuse large B-cell lymphoma（DLBCL）.Methods Serum VEGF in 41 patients with DLBCL（group A） and 36 healthy people（group C） was detected by ELISA.The clinical features of patients with DLBCL were recorded and the therapeutic effect of chemotherapy was evaluated after chemotherapy with CHOP.Results Serum VEGF before therapy was higher in group A than that in group C[（219.1±34.5） pg/ml vs.（122.6±26.4） pg/ml]（P〈0.05）.In the cases with positive response to chemotherapy in group A,serum VEGF after treatment was reduced more than that before（P〈0.05）.There were significant differences in the levels of VEGF among different levels of lactate dehydrogenase（LDH）,clinical stages,bone marrow infiltration and the numbers of focus of infection（P〈0.05）.Conclusion Serum VEGF expression is related to the development and progression of DLBCL and can be used for evaluating the therapeutic effect of chemotherapy and prognosis of DLBCL.
出处
《江苏医药》
CAS
CSCD
北大核心
2011年第20期2383-2384,共2页
Jiangsu Medical Journal
基金
江苏省常州市卫生创新人才培养工程资助项目
